![LDKT](https://www.adcreviews.com/wp-content/uploads/2022/10/LDKT-240x129.jpg)
FCR001 subject dies, Talaris stock price plummets
On October 20, Talaris announced the latest progress of the Phase III FREEDOM-1 study of its investigational allogeneic cell therapy FCR001 for inhibiting acute immune
On October 20, Talaris announced the latest progress of the Phase III FREEDOM-1 study of its investigational allogeneic cell therapy FCR001 for inhibiting acute immune